Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Serine Protein Kinase ATM is a serine/threonine protein kinase. It plays a role in replication-dependent histone mRNA degradation. The Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development market research report provides an in-depth analysis of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
Mechanisms of Action of Serine Protein Kinase ATM Pipeline Market
The mechanisms of action of the Serine Protein Kinase ATM pipeline market Serine Protein Kinase ATM Inhibitor and Serine Protein Kinase ATM Activator.
Serine Protein Kinase ATM pipeline market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Serine Protein Kinase ATM Pipeline Market
The routes of administration in the Serine Protein Kinase ATM pipeline market are oral and intravenous bolus.
Serine Protein Kinase ATM pipeline market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Serine Protein Kinase ATM Pipeline Market
The molecule types in the Serine Protein Kinase ATM pipeline market are small molecule and antisense RNAi oligonucleotide.
Serine Protein Kinase ATM pipeline market, by molecule types
For more molecule type insights, download a free report sample
Key Serine Protein Kinase ATM Pipeline Market Companies
The key companies in the Serine Protein Kinase ATM pipeline market are AstraZeneca Plc, IMPACT Therapeutics Inc, InteRNA Technologies BV, Merck KGaA, Shuttle Pharmaceuticals Inc, and XRad Therapeutics Inc.
Serine Protein Kinase ATM pipeline market, by companies
To know more about key companies, download a free report sample
Market report overview
Mechanisms of Action | Serine Protein Kinase ATM Inhibitor and Serine Protein Kinase ATM Activator |
Routes of Administration | Oral and Intravenous Bolus |
Molecule Types | Small Molecule and Antisense RNAi Oligonucleotide |
Key Companies | AstraZeneca Plc, IMPACT Therapeutics Inc, InteRNA Technologies BV, Merck KGaA, Shuttle Pharmaceuticals Inc, and XRad Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1).
- Reviews of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) therapeutics and enlists all their major and minor projects.
- Assessment of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1).
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
IMPACT Therapeutics Inc
InteRNA Technologies BV
Merck KGaA
Shuttle Pharmaceuticals Inc
XRad Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the mechanisms of action of the Serine Protein Kinase ATM pipeline market?
The mechanisms of action of the Serine Protein Kinase ATM pipeline market are Serine Protein Kinase ATM Inhibitor and Serine Protein Kinase ATM Activator.
-
What are the routes of administration in the Serine Protein Kinase ATM pipeline market?
The routes of administration in the Serine Protein Kinase ATM pipeline market are oral and intravenous bolus.
-
What are the molecule types in the Serine Protein Kinase ATM pipeline market?
The molecule types in the Serine Protein Kinase ATM pipeline market are small molecule and antisense RNAi oligonucleotide.
-
Which are the key companies in the Serine Protein Kinase ATM pipeline market?
The key companies in the Serine Protein Kinase ATM pipeline market are AstraZeneca Plc, IMPACT Therapeutics Inc, InteRNA Technologies BV, Merck KGaA, Shuttle Pharmaceuticals Inc, and XRad Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.